Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.47 |
| ▸ | MAP2K2 | P36507 | 13/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6186545 | 0.92 | MAP2K1 (0.40) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL6397573 | 0.86 | RXFP1 (0.33) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL6186539 | 0.85 | MAP2K1 (0.48) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL6188842 | 0.85 | GSK3B (0.33) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL6206971 | 0.85 | MAP2K1 (0.38) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL6206562 | 0.85 | MAP2K1 (0.46) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL6208327 | 0.85 | MAP2K1 (0.52) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL6399219 | 0.83 | MAP2K1 (0.43) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL6187354 | 0.83 | MAP2K1 (0.48) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL6206196 | 0.83 | IRAK4 (0.34) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | claimed |
| EP-1578736-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1529045-A2 | NEW COMPOUNDS | Astra Zeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| WO-2004056789-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004014881-A2 | '1,2,4'OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRA ZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | MAPK1, MAP3K1, MAPK3 | MAP2K1 46/4885MAP2K2 40/4885BRAF 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.